The FDA will approve a new drug well ahead of the PDUFA schedule when there is a compelling medical need. Roche’s Zelboraf (f/k/a PLX4032) and JNJ’s Zytiga are two such cases.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”